

The Effect of Additional Nanoparticles Supplementation of Indonesian Bay Leaf (*Syzygium Polyanthum*) on Blood Pressure in Pregnancy Hypertension

Miftah Nurlaily El Akhlaq^{1*}

¹ Poltekkes Kemenkes Semarang, Master of Applied Science in Midwifery, Tirta Agung Rd., Semarang, Jawa Tengah 50268, Indonesia

Suharyo Hadisaputro²

Poltekkes Kemenkes Semarang, Master of Applied Science in Midwifery, Tirta Agung Rd., Semarang, Jawa Tengah 50268, Indonesia

Suhartono³

Department of Environmental Health, Faculty of Public Health, Diponegoro University, Prof. Sudarto Rd., Semarang, Jawa Tengah 50275, Indonesia

Sri Sumarni⁴

⁴Poltekkes Kemenkes Semarang, Master of Applied Science in Midwifery, Tirta Agung Rd., Semarang, Jawa Tengah 50268, Indonesia

M. Choirel Anwar⁵

Poltekkes Kemenkes Semarang
Postgraduate Program of Imaging Diagnostic
Tirta Agung Rd., Semarang, Jawa Tengah 50268,
Indonesia

Abstract:- Bay leaf (*Syzygium polyanthum*) or Daun Salam is one of the plants that has many benefits, one of them is to reduce blood pressure. The aim of this study is to prove the effect of adding nanoparticles supplementation of bay leaf (*Syzygium polyanthum*) to systolic and diastolic blood pressure in pregnancy hypertension. The study was quasi-experiment. 39 respondents were divided into 19 pregnant women in intervention group and 20 pregnant women in the control group. The intervention was given for 14 days by consuming nifedipine 10mg plus 80mg bay leaf nanoparticle capsules to the intervention group. The results of data analysis showed a decrease in systolic blood pressure ($p = 0.000$) and diastolic blood pressure ($p = 0.004$) when compared with the control group, which means that there were differences in the mean systolic and diastolic blood pressure between the two groups after treatment. The addition of bay leaf nanoparticle supplementation 1x80 mg for 14 days affected the decrease in systolic and diastolic blood pressure in pregnancy hypertension. So that the supplementation of bay leaf nanoparticles can be used as adjunctive therapy in pregnancy hypertension

475 cases. Most deaths are caused by pregnancy hypertension, with the percentage of 32,97%, and the highest number of cases were coming from Brebes Regency.[3] The number of maternal mortality, in 2017, from this regency was 31 cases from 95/100.000 live births.[4]

Hypertension in pregnancy can be a severe condition if it is not treated. It is because of its emerged complications. 25% of pregnancy hypertension cases can turn into *superimposed preeclampsia*. [5]

To control these mentioned problems, the management of pregnancy hypertension can be done pharmacologically and non-pharmacologically. Pharmacological anti-hypertensive therapy is inseparable from its side effects. The side effects are ranging from: sleep disturbance, bronchospasm, decreased uteroplacental flow, fetal distress, or a dramatic decrease in magnesium.[6] Non-pharmacological therapy for hypertension that has been tried in clinical trials is the use of herbs, *device-guided breathing*, and other *biofeedback*. [7]

Indonesian Bay Leaf (*Syzygium polyanthum*) is a plant that has an anti-hypertensive effect because of its antioxidant content. Phenolic and flavonoids such as eugenol, kaempferol, and quercetin contribute to the antioxidant activity of bay leaves.[8] Processing of herbal ingredients using nanoparticle technology shows an increasing trend because the bioavailability of nanoparticles is considered to be better in the process of absorption of active ingredients by the small intestinal wall.[9] Previous research of hypertensive patients with treatment of drinking bay leaf decoction two times, showing the results that the bay leaf decoction water can

Keywords:- Bay leaf, Blood pressure, Gestational hypertension.

I. INTRODUCTION

Pregnancy hypertension is one of the causes of maternal morbidity and mortality in the world. Based on data from the World Health Organization (WHO), in 2015, there are approximately 289.000 cases of maternal mortality, and 14% of those cases are pregnancy hypertension.[1] The maternal mortality rate in Indonesia was 177 deaths per 100.000 live births in 2017.[2] The number of maternal mortality in Central Java, in 2017, was

reduce blood pressure because its minerals can dilate blood vessels.[10]

Referring to previous research, there has been no research on the provision of bay leaves with nanotechnology processing technology in hypertension that occurs in pregnancy. By considering the toxicity of the material, we, as researchers, are interested in conducting research to determine the effect of supplementation of bay leaf nanoparticles (*Syzygiumpolyanthum*) on systolic and diastolic blood pressure of pregnant women with pregnancy hypertension.

II. OBJECTIVES

This study aims to prove the effect of adding supplementation of bay leaf nanoparticles (*Syzygiumpolyanthum*) on the decrease in systolic and diastolic blood pressure of pregnant women with pregnancy hypertension.

III. METHODS

This study was *Quasi-Experiment* with a *non-randomized* pre-test and post-test with *control group design*. The reference population in this study were pregnant women of gestational age >20 weeks - 38 weeks with pregnancy hypertension. Samples in the intervention group were 19 people, and in the control group were 20 people. The intervention group was given 80 mg bay leaf nanoparticles and 10 mg nifedipine, while the control group was only given 10 mg nifedipine.

The sampling technique uses a *non-probability sampling* method with the type of *purposive sampling*.

The instrument in this research is a digital tension meter which had been validated.

The data is collected after obtaining an ethical eligibility letter from the Health Research Ethics Committee (KEPK) RSUD Dr. Moewardi with letter number 1.398 / XII / HREC / 2019.

Analysis of blood pressure before and after treatment using a *paired t-test*, and to determine the differences between the two groups using the *independent t-test*.

IV. RESULTS

Variable	p-value*	
	Intervention	Control
Systolic Blood Pressure		
Pre	0.280	0.710
Post	0.185	0.943
Delta	0.248	0.097
Diastolic Blood Pressure		
Pre	0.062	0.501
Post	0.285	0.380
Delta	0.203	0.586

*Shapiro-Wilk

Table 1:- Normality Test

Table 1 shows the normality test of systolic and diastolic blood pressure. Normality test results show that the p-value is more than 0.05, so it wrapped that the data are normally distributed so it can be continued using the parametric test.

Systolic Blood Pressure	Intervention Group	Control Group	
	Mean ± SD	Mean ± SD	p value
Pre-test	151.53 ± 4.97	151.20±6.27	0.859**
Post-test	139.84 ± 7.59	151.40±6.96	< 0.001**
Delta	11.68 ± 5.47	-20 ± 3.433	< 0.001**
p – value	< 0.001*	0.798*	

* Paired t –test

** Independent t-test

Table 2:- Systolic Blood Pressure Result

Table 2 illustrated the average systolic blood pressure in the intervention group. It was 151.53 mmHg and decreased to 139.84 mmHg. The result of *paired t-test* analysis in the intervention group showed a *p-value*<0.05, which means that there was a difference in systolic blood pressure before and after the intervention.

While the mean systolic blood pressure in the control group was 151.20 mmHg, and it decreased into 151.40 mmHg. The result of *paired t-test* analysis in the control group showed a *p-value*> 0.05, which means there was no difference in systolic blood pressure before and after the intervention.

Based on the results of the *Independent t-test* showed that the value of *p* = 0.859 > 0.05, which means there was no difference in the average systolic blood pressure between the intervention group and the control group before being treated. After treatment, the result was *p* = 0.000 <0.05, which means that there was a difference in the average systolic blood pressure after being treated in the two groups

Diastolic Blood Pressure	Intervention Group	Control Group	
	Mean ± SD	Mean±SD	<i>p value</i>
Pre-test	104.79±6.60	106.20±9.54	0.597**
Post-test	92.84 ± 8.71	101.85±9.33	0.004**
Delta	11.95±5.642	4.35 ± 6.167	< 0.001**
<i>p value</i>	< 0.001*	0.005*	

* *Paired t-test*

** *Independent t-test*

Table 3:- Diastolic Blood Pressure Result

Table 3 illustrated the average diastolic blood pressure in the intervention group. It was 104.79 mmHg and decreased to 92.84 mmHg. The result of *paired t-test* analysis in the intervention group showed a *p-value*<0.05, which means that there was a difference in systolic blood pressure before and after the intervention.

While the mean diastolic blood pressure in the control group was 106.20 mmHg, and it decreased into 101.85 mmHg. The result of *paired t-test* analysis in the control group showed a *p-value*<0.05, which means that there was a difference in diastolic blood pressure before and after the intervention.

Based on the result of the *Independent t-test* showed that the value of *p* = 0.597 > 0.05, which means there was no difference in the average diastolic blood pressure between the intervention group and the control group before being treated. After the treatment, the result was *p* = 0.004 <0.05, which means that there was a difference in the average diastolic blood pressure after being treated in both groups

V. DISCUSSION

The mean systolic blood pressure and diastolic blood pressure in the intervention group and the control group showed that there were no differences between the two groups before intervention with *p* = 0.859 and *p* = 0.597. Meanwhile, after treatment, it was obtained that there were differences between the two groups with *p* values = 0.000 for systolic blood pressure and *p* = 0.004 for diastolic blood pressure.

The results of this research are in line with research conducted by ArifalAris (2018), which stated that the provision of bay leaf decoction could reduce blood pressure in hypertensive patients. The analysis showed *p* = 0.000. At first, there were 7 (21.9%) patients with moderate hypertension and decreased to 6 (18.8%) patients after being given treatment. Furthermore, 16 patients or respondents, who experienced mild hypertension before being treated, changed to normal categories after being given a decoction of bay leaves.[11]

This was also supported by another study conducted by Sri Margowati (2016) that giving bay leaf decoction influenced the decrease in systolic and diastolic blood pressure (*p* <0.05) with an average reduction in systolic blood pressure of 24.97 mmHg and diastolic blood pressure at 12.65 mmHg. This research showed the systolic mean value after being given intervention was 149.09, and the diastolic mean value was 84.4.[12]

The content of flavonoids in bay leaves (*Syzygiumpolyanthum*) can help lower blood pressure by improving endothelial function and inhibiting platelet aggregation in humans, thus providing benefits, especially in cardiovascular disease.[12] Endothelium situated in the location between blood and smooth muscle of blood vessels and produces various substances that can maintain the homeostasis and health of blood vessels. Various things that damage the endothelium can cause endothelial dysfunction, resulting in hypertension and other cardiovascular diseases. Hypertension is a sign of damage to the endothelium associated with inflammatory response, oxidative stress, and dysfunction of the smooth muscle of the heart's blood vessels.[13]

Flavonoids are substances that can free radicals that inhibit lipid peroxide, prevent atherosclerosis, and provide cardioprotective effects. In a study by Houston on nutrition and supplementation for the treatment of hypertension, the recommended daily dose of flavonoids was 250 grams.[13]

VI. CONCLUSION

Supplementation of 80mg dose of bay leaf nanoparticles (*Syzygiumpolyanthum*) for 14 days in pregnancy hypertensive patients who received nifedipine 10mg affected the reduction in systolic blood pressure by ± 11.68 mmHg and diastolic blood pressure of ± 11.95 mmHg in the intervention group compared to with a control group.

ACKNOWLEDGMENT

We are incredibly grateful for our supervisor in this research and the entire academic community of the Polytechnic of the Ministry of Health Semarang for the opportunity that has been given.

REFERENCES

- [1]. S. Gainer, M. Thakur, S. C. Saha, and M. Prakash, "To Study The Changes in Fetal Hemodynamics With Intravenous Labetalol or Nifedipine in Acute Severe Hypertension," *Pregnancy Hypertens. An Int. J. Women's Cardiovasc. Heal.*, 2018.
- [2]. WHO, *World Health Organization Statistics*. 2015.
- [3]. S. Susiana, "Angka Kematian Ibu : Faktor Penyebab Dan Upaya Penanganannya," *Pus. Penelit. Badan Keahlian DPR RI*, vol. XI, no. II, 2019.
- [4]. Dinas Kesehatan Provinsi Jawa Tengah, *Profil Kesehatan Provinsi Jawa Tengah 2017*, vol. 3511351, no. 24. Semarang: DKK Provinsi Jawa Tengah, 2018.
- [5]. D. K. K. Brebes, *Profil Kesehatan Kabupaten Brebes 2017*. Jawa Tengah, 2017.
- [6]. A. G. Kattah and V. D. Garovic, "The Management of Hypertension in Pregnancy," *Adv. Chronic Kidney Dis.*, vol. 20, no. 3, pp. 229–239, 2013.
- [7]. S. S. Hedayati, E. F. Elsayed, and R. F. Reilly, "Non-pharmacological aspects of blood pressure management: What are the data?," *Kidney Int.*, vol. 79, no. 10, pp. 1061–1070, 2011.
- [8]. M. D. Hidayati, T. Ersam, K. Shimizu, and S. Fatmawati, "Antioxidant Activity of Syzygium Polyanthum Extracts," *Indones. J. Chem.*, vol. 17, no. 1, pp. 49–53, 2017.
- [9]. N. Jusnita and W. Syurya, "Karakterisasi Nanoemulsi Ekstrak Daun Kelor (Moringa oleifera Lamk .)," *J. Sains Farm. dan Klin.*, vol. 6, no. 1, pp. 16–24, 2019.
- [10]. P. Dafriani, "Pengaruh Rebusan Daun Salam (Syzygium Polyanthum Wight Walp) Terhadap Tekanan Darah Pasien Hipertensi di Sungai Bungkal, Kerinci 2016," *J. Med. Saintika*, vol. 7, pp. 25–34, 2016.
- [11]. A. Aris, "Pengaruh Pemberian Rebusan Daun Salam (Syzygium Polyanthum) Terhadap Penurunan Tekanan Darah Tinggi di Desa Plosowahyu Kecamatan Lamongan Kabupaten Lamongan," *Pros. Semin. Nas.*, pp. 199–208, 2018.
- [12]. S. Margowati, S. Priyanto, and M. Wiharyani, "Efektivitas Penggunaan Rebusan Daun Alpukat Dengan Rebusan Daun Salam Dalam Penurunan Tekanan Darah Pada Lansia," *Universty Res. Coloquium*, pp. 234–248, 2016.
- [13]. M. Houston, "The role of nutrition and nutraceutical supplements in the treatment of hypertension," *World J. Cardiol.*, vol. 6, no. 2, p. 38, 2014.